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When Louis Pasteur concluded in a biblical tone his speech
describing the results that demolished the theory of spontaneous
generation by saying: Messieurs, c’est les microbes qui auront
le dernier mot, a new era for humankind had began. He
discovered the rational basis for microbial fermentations, for
the development of vaccines, etc. He developed, without
knowing it, the scientific basis of modern biotechnology. Now,
more than a century later, at the end of the 20th century, there
is a general agreement among scientists, politicians and
sociologists: that the 21st century will be the century of
Biotechnology and of Life Sciences [1]. 
Since the early 1980’s, the European Union (EU) has
developed several research and training programmes in
Biotechnology, Biomedicine and Health as well as on Food
and Agro-industrial research. These programmes have
succeeded in mobilising, in an interdisciplinary and
collaborative way, the most dynamic scientific and industrial
groups in Europe, and they have provided an excellent record
for research for the life sciences. The Life Sciences Community
programmes have also generated an explosion in the knowledge
of the structure and habits of all living beings, and in particular
of living cells. This leads to promising developments in the
corresponding sectors, e.g. health-care, pharmaceuticals,
agriculture, food, etc. These developments, however, have been
fulfilled only partially, as Europe has not been strong enough
to exploit the advances steaming from this research. 
The socio-economic objective of the Fifth
Framework Programme
The Fifth Framework Programme for Research, Technological
Development and Demonstration (1998–2002) [2] has taken
into account the new socio-economic reality and has, therefore,
adopted a new approach. Its novelty is the political willingness
to couple the dynamics of massive knowledge production with
the few areas from which desirable spin-offs are expected to
arise. Meanwhile, the Programme will pursue the renewal of
knowledge to reinforce European strength in fields associated
with further growth and higher standards of life. This is the
purpose behind European research, as indicated by the
Commission in the Inventing Tomorrow’s document [3], which
has served as the basis for the preparation of the Fifth
Framework Programme. 
There is no doubt that scientific, technological progress
increasingly determines the way and the speed at which society
evolves. This raises inevitably a certain number of questions, in
particular with respect to the speed of the changes and the
directions which they are taking in society. But one can also turn
the approach around: if the role of research and technological
development is to innovate, is this not in order to respond to a
large extent to social and economic needs and expectations?
From the perspective of Community policy, research is not
an end in itself, but rather an extremely important tool to achieve
common objectives. The EU considers that now it is time to
change direction slightly in order to put research activities in
the current socio-economic context. Hitherto, Community
research activities have been largely based on a technology-
driven approach. The aim of the Fifth Framework Programme
is to make research more efficient, in terms of exploitation of
research results, directed towards meeting basic social and
economic needs by bringing about the changes which each
individual citizen desires. 
To sum up, the Fifth Framework Programme consists of
four thematic programmes and three horizontal programmes.
The thematic programmes with the corresponding budgets
expressed in million of euros (M ) are: 
• Quality of life and management of living resources
(2,413 M ); 
• User-friendly information society (3,600 M ); 
• Competitive and sustainable growth (2,705 M );
• Energy, environment and sustainable development
(2,125 M ).
Alfredo Aguilar
European Commission, Brussels, Belgium
Correspondence to: 
European Commission. Directorate General XII.
Science, Research and Development. 
Directorate Life Sciences. Cell Factory Unit.
200, Rue de la Loi. B-1049 Brussels. Belgium.
Tel.: +32-2-2961481. Fax: +32-2-2991860. 
E-mail: alfredo.aguilar-romanillos@dg12.cec.be
PERSPECTIVES
INTERNATL MICROBIOL (1999) 2:121–124
© Springer-Verlag Ibérica 1999
The key action Cell Factory, an
initiative of the European Union
This article expresses the personal opinion of the author and does not,
necessarily, reflect the official opinion of the European Commission.
c
c
c
c
c
The horizontal programmes address the following three
themes, respectively: 
• Confirming the international role of Community research
(475 M ); 
• Promotion of innovation and encouragement of
participation of SMEs (363 M );
• Improving human research potential and socio-economic
knowledge base (1,280 M ).
The Quality of Life and Management 
of Living Resources Programme
This Programme has a budget of 2,413 M [4], which is a
significant increase over the RTD activities in Life Sciences from
the Fourth Framework Programme (1994–1998). The strategic
objective is to link the ability to discover with the ability to produce
in order to address the needs of society, and to meet the
requirements of the consumer, leading to future wealth and job
creation and improvements in the environment. The strategy of
the socio-economic drive of this programme is to focus on specific
areas where growing knowledge may provide scientific and
technical answers to some of the pressing questions asked by the
European citizen, which requires tackling on a European scale.
The Quality of Life Programme will concentrate on the
acquisition and utilization of knowledge on fundamental
mechanisms affecting human life, especially in the fields of
health, food and environment. Particular emphasis will be
placed on the development of knowledge aimed at the
prevention of disease (research on the brain, on the
mechanisms of food poisoning, on the newly emerging
infectious diseases, etc.). The exploitation of living cells
for health, environment and agro-industry and fine chemicals
is also equally considered. 
The programme has an overall concern to maximize the
quality, the safety and renewable nature of bioproduction while
respecting the fundamental ethical values. The six key actions
with their financial breakdown (in M ) are the following: 
(i) Food, Nutrition and Health (290 M ), (ii) Control of
infectious diseases (300 M ), (iii) The “Cell Factory” (400
M ), (iv) Environment and Health (160 M ), (v) Sustainable
agriculture, fisheries and forestry, and integrated development
of rural areas including mountain areas (520 M ), and (vi) The
ageing population and disabilities (190 M ). 
The key actions will concentrate on targeted, clearly
delimited socio-economic needs and on the Community’s policy
objectives, where European research should make a decisive
contribution with innovative products, processes or services.
The key actions are supplemented in the programme with
research and technological development of a generic nature as
well as support to research infrastructures. The activities of
generic nature have a long-term impact. Their aim is to help
the Community not only to maintain but also to improve its
scientific and technological capability in those areas of research,
and to enable technologies that should be widely used. The
budget allocated by the Council to generic activities is of 
483 M . Support will be focused on: 
• Chronic and degenerative diseases (in particular cancer
and diabetes), cardiovascular diseases and rare diseases
• Research into genomes and diseases from genetic origin
• Neurosciences
• Public health and health services research 
• Research related to the disabled
• Study of problems related to medical ethics and bioethics
in the context of respect for fundamental human values
• Study of the socio-economic aspects of life sciences and
technologies within the perspective of sustainable
development (the impact on society, economy and
employment)
The activities on research infrastructures in the programme
should be able to provide added value, complementary to
national or multinational initiatives. The following classes of
infrastructures will be supported within a budget of 70 M and
will focus on: 
• Biological data and collections of biological material
• Clinical research facilities, including pre-clinical
research 
• Facilities for aquaculture and fisheries research
The first call for proposals for the Quality of Life Programme
has been published recently [5]. The text of the Work programme,
and general information is available from the Commission services
at the following addresses: 
E-mail: life@dg12.cec.be
Web: http://www.cordis.lu/fp5/home.html
Key action: the “Cell Factory”
Worldwide sales of about twenty cell-derived molecules
produced on a large scale (insulin, interferon, erythropoietin,
etc.) already amount to 9.35 billion euros. The recent strategic
changes in the chemical industry are now concentrating on
life sciences, as opposed to the traditional chemical sectors.
Those changes reveal the issues involved in the extremely
rapid growth of this scientific and technological domain. In
less than five years, the world market for bio-products,
especially in the health and environment fields, could amount
to 100 billion euros with the added perspective of creating
200,000 new jobs. 
Europe possesses first class scientific groups and an
excellent know-how of this exploitation of living resources.
All too often, however, the commercial exploitation takes place
elsewhere, particularly in the USA. This key action on Cell
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Factory should make it possible to strengthen the European
capabilities in this domain by encouraging multidisciplinary
approaches, which are indispensable to understand how cells
work, and to develop viable applications in health, agriculture
and industry. The industrial mastery of the cell as a factory
opens up revolutionary perspectives. Development of new kinds
of drugs, foodstuffs with specific nutritional properties,
techniques for biodegradation of recalcitrant compounds,
industrial enzymes replacing less environmentally friendly
chemical processes, etc.
The overall objective of this key action is to integrate the
innovations into living cells (microbial, plant and animal cells)
and into their productions. Thus, they would provide an
environment in which results could rapidly be exploited and
transformed into products and processes of interest to the
society. The spin-offs in society will be particularly visible in
the health, environment, food, agriculture, agro-industries and
high value-added products.
Contrary to previous framework programmes, which were
mainly knowledge and technology-driven, the Fifth Framework
Programme, and in particular this key action, has taken a
different approach. It consists of putting forward the main socio-
economic objectives addressed by the key action, together with
the anticipated deliverables to society. In order to attain such
objectives and deliverables, the key action will mobilise any
kind of research or technological development, including
demonstrations geared to the fulfillment of the overall
objectives. 
European challenges to be addressed by
the Cell Factory key action 
Promoting the development of innovative technologies
and mobilising mission oriented research The new
knowledge on advanced research that will be generated by
the functioning of the cells as biological factories needs to
be integrated into the overall problem solving approach of
the key action.
Exploitation of results The creation of wealth and employment
requires close links between research and socio-economic
needs, efficient risk capital markets, creation and development
of high-tech SMEs and a fruitful dialogue between knowledge
and technology producers. The challenge Europe faces is to
set up a nurturing environment for the development both of
established bio-industries and of a new generation of European
entrepreneurs to start up and flourish. 
Linking the ability to discover to the ability to produce
Scientific and technological excellence of the selected project
is, indeed, necessary but not sufficient. It should be closely
commited to knowledge transfer and convincing exploitation
potential. 
Anticipated deliverables
The key action will mobilize the efforts to seize opportunities
in the following three areas of high socio-economic interest: 
Improving the diagnostic and therapeutic arsenal for health
care: development of new or improved health related processes
and products from living cells and biomolecules, particularly
towards improved therapeutics: new antibiotics, anticancer
therapies, etc.; in vitro alternative tests, diagnostic tests,
innovative technologies for biological production and novel
targets for drug discovery.
Improving environmental sustainability: development of
cleaner technologies and improvement of bioremediation and
waste biotreatment processes. These efforts will be driven towards
environmental friendly products and processes, recycling and/or
biodegradation of wastes and industrial by-products; bioassays
to monitor the effects of toxic chemicals in biological systems,
and methods and strategies for safe introduction, use, monitoring
and tracing of genetically modified organisms (GMOs).
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Table 1 Action lines under the key action the Cell Factory
New and innovation health-related processes and products
• Development of new diagnostics, therapeutic substances and strategies
Diagnostics
Therapeutic substances
Therapeutic strategies — Gene Therapy — Tissue and cell engineering
• New and improved technologies for biological productions
• Novel in vitro testing as alternatives to animal testing
Energy-efficient bioremediation and waste biotreatment processes
• New bioprocesses for preventing industrial pollution, treating, upgrading,
and/or recycling bioaccumulable wastes and industrial by-products
• Bioassays and biosensors
• Biodegradation of recalcitrant chemicals
• Biodiversity and ecological dynamics of natural and introduced populations
Microorganisms
Plants and animals
• Development of methods and strategies to ensure the safety of new
biomolecules or bioprocesses, and for the identification of recombinant
organisms and their residues in the environment and their impact on human
and animal health
New biological and biotechnological processes and products from cell
factories
• Exploiting the cellular and molecular characteristics of organisms
• High value-added products and processes involving/derived from
microorganisms, plants and animals
Microorganisms
Animals
Plants
• Functional biomolecules and biocatalysts
• Identification and sustainable use of metabolic and genetic diversity as a
source of new valuable products
Improving quality in food, agro-industry and fine chemicals:
the key action aims at the development of bio-processes and
bio-products combining ecological, consumer and industrial
advantages, particularly towards high value-added products
and processes for food, agro-industry and the (bio)chemical
sectors including fine chemicals, and products derived from
improved crops and farm animals.
Research and Technological Development
(RTD) to be mobilised to attain the 
socio-economic objectives 
The EU has departed in the current Fifth Framework
Programme  from the classical linear innovation chain: that
is to say from basic and applied research through technological
and industrial development to industrial production. In fast
developing high-tech fields such as those involved in life
sciences, the innovation chain does not always proceed
following the classical mechanism. In certain cases, the fast
dynamics of the innovation and the competitive forces of the
market do not allow the time to follow the classical innovation
chain. The product may be already obsolete before reaching
the market. In other cases, because the science and technology
push are not in phase with the needs expressed by society or
the market pull. Finally, in countries where scientific and
industrial tissues have not reached the dimension and the level
of the more advanced ones, scientific and technological
communities are relatively small. Scientific activities usually
constitute an end in themselves without sufficient integration
in the other social spheres. As a result, the impact of the research
reaching society is unsatisfactory.
The approach of the EU has been pro-active. Rather than
having a passive role waiting for an uncertain transfer of results
to industry and society, the Commission has identified the potential
necessities with the help of external advisory groups (EAG’s),
(one EAG focused on the Cell Factory key action) [6], scientific
and industrial communities, socio-economic groups, etc. 
The EAG on Cell Factory has delivered a number of key
messages and most of them have been incorporated in the
Workprogramme. The projects supported must combine
innovative and multidisciplinary technology platforms with
convincing dissemination and exploitation strategies, either by
established industries, small biotech firms, entrepreneurial
initiatives or by the public sector. The Commission was asked
to apply a reasonable flexibility to the RTD fields to be
mobilised. The projects could address a wide spectrum of RTD
targets, provided they focused on the main socio-economic
objective of the key action. In short, good, scientific excellence
is necessary but not sufficient. Knowledge transfer and
exploitation commitment are also essential. Another important
message is that the Cell Factory key action does not exclude
basic or fundamental research, nor does it focus on applied
research. It should mobilise whatever scientific excellence,
innovative technologies and convincing exploitation strategies
are needed to reach the socio-economic objectives. It should
also address the problem-solving approach of this key action,
thereby leaving room for innovative ideas from the applicants. 
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